Abstracts tagged "Psoriatic arthritis"

Abstract Number: 961 • 2016 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial
Philip J Mease¹, Arthur Kavanaugh², Andreas Reimold³, Hasan Tahir⁴, Juergen Rech⁵, Stephen Hall⁶, Piet Geusens^7,8, Pellet Pascale⁹, Evie Maria Delicha¹⁰, Luminita Pricop¹¹ and Shephard Mpofu¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²UC San Diego School of Medicine, La Jolla, CA, ³Dallas VA Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁶Monash University, Melbourne, Australia, ⁷University of Hasselt, Hasselt, Belgium, ⁸Maastricht University Hospital, Maastricht, Netherlands, ⁹Novartis Pharma AG, basel, Switzerland, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, provided rapid and significant improvements in the key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study…
Abstract Number: 1728 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Mehmet Ali Balci¹, Mustafa Ferhat Oksuz², Salim Donmez¹, Tugce Ozen³, Ediz Dalkilic², Ayse Nur Tufan², Yavuz Pehlivan² and Omer Nuri Pamuk⁴, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, ³PHYSICAL THERAPY AND REHABILITATION, Trakya University Faculty of Health Sciences, Edirne, Turkey, ⁴Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey
Background/Purpose: Psoriatic arthritis (PsA), Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are an inflammatory arthritis causing joint damage and disability. Non-adherence to disease modifying anti-rheumatic…
Abstract Number: 1326 • 2016 ACR/ARHP Annual Meeting
Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease
Sheila Arvikar¹, Jameson Crowley¹, Katherine Sulka² and Allen C. Steere³, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Charlestown, MA, ²Rheumatology Allergy and Immunology, Massachusetts General Hospital, Charlestown, MA, ³Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lyme arthritis (LA) usually responds to antibiotic therapy, though immune-mediated synovitis may persist after antibiotic treatment, usually confined to a previously infected joint,…
Abstract Number: 1729 • 2016 ACR/ARHP Annual Meeting
Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
Vibeke Strand¹, Philip J Mease², Iain B McInnes³, Peter Nash⁴, Howard Thom⁵, Matthias Hunger⁶, Kunal Gandhi⁷, Shephard Mpofu⁸ and Steffen Jugl⁸, ¹Stanford University School of Medicine, Palo Alto, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ⁵University of Bristol, Bristol, United Kingdom, ⁶MAPI Group, Munich, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and infliximab (INF) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. There are…
Abstract Number: 1422 • 2016 ACR/ARHP Annual Meeting
Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study
Tanja Schjødt Jørgensen¹, Louise Klokker¹, Henrik Gudbergsen², Simon Francis Thomsen³, Robin Christensen⁴, Henning Bliddal¹ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg,, Copenhagen, Denmark, ³Department of Dermatology, Bispebjerg Hospital & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
Identifying generic and specific patients’ perspectives on disease- and treatment-related issues in rheumatoid arthritis, psoriatic arthritis, and psoriasis: a qualitative concept mapping studyT.S. Jørgensen1, L.…
Abstract Number: 1731 • 2016 ACR/ARHP Annual Meeting
Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients
Arthur F. Kavanaugh¹, Philip J. Mease², Oana Purcaru³ and Désirée van der Heijde⁴, ¹Division of Rheumatology, Allergy, and Immunology, UC San Diego School of Medicine, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³208 Bath Road, UCB Pharma, Slough, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), can impact…
Abstract Number: 1423 • 2016 ACR/ARHP Annual Meeting
Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis
Stephen Doogan¹, John Heid², Samir Benosman³, Alexis Ogdie⁴, Layne Martin⁵, Prashanth Sunkureddi⁶ and Jacqueline Palmer⁷, ¹Real Life Sciences, New York, NY, ²Kinapse, Inc, London, United Kingdom, ³Advisory Services, Kinapse, Inc, London, United Kingdom, ⁴University of Pennsylvania, Philadelphia, PA, ⁵CreakyJoints, NY, ⁶Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a debilitating disease with significant impact on patient quality of life (QoL). While patient reported outcome (PRO) instruments broadly capture…
Abstract Number: 1733 • 2016 ACR/ARHP Annual Meeting
Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
Kim Papp¹, Alice B. Gottlieb², Catherine L. Shuler³, Russel T. Burge³, Gregory Cameron³, Lisa Kerr³ and Philip J Mease⁴, ¹K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ²Tufts University School of Medicine, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
Abstract Number: 1651 • 2016 ACR/ARHP Annual Meeting
A Case Series on Patients on Tofacitinib in Combination with a Biologic
Nashla Barroso¹ and Daniel E. Furst², ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although there have been significant advances in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). patients can experience a lack of or…
Abstract Number: 1734 • 2016 ACR/ARHP Annual Meeting
Apremilast Is Associated with Long-Term DAS-28 (CRP) Remission and Improvements in Skin Disease: Results from a Phase III Study in DMARD/Biologic-Experienced Active Psoriatic Arthritis Patients
Christopher J Edwards¹, Francisco J Blanco², Jeffrey J Crowley³, Melissa McIlraith⁴, Kamal Shah⁴, Nikolay Delev⁴, Lichen Teng⁴ and Charles A Birbara⁵, ¹University Hospital Southampton, Southampton, United Kingdom, ²INIBIC-Hospital Universitario A Coruña, Galicia, Spain, ³Bakersfield Dermatology, Bakersfield, CA, ⁴Celgene Corporation, Summit, NJ, ⁵University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Treatment goals for long-term control of skin and joint symptoms in active psoriatic arthritis (PsA) include clinically important changes in DAS-28 (CRP), achievement of…
Abstract Number: 1676 • 2016 ACR/ARHP Annual Meeting
Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gia Deyab¹, Ingrid Hokstad², Stefan Agewall³, Torstein Lyberg⁴, Jon Elling Whist⁵, Milada Cvancarova Småstuen⁶, Gunnbjørg Hjeltnes⁷ and Ivana Hollan^8,9,10,11, ¹Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, ²Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, ³University of Oslo, Oslo, Norway, ⁴Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁵Innlandet Hospital Trust, Lillehammer, Norway, ⁶Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, ⁷Medicine, Innlandet Hospital Trust, Lillehammer, Norway, ⁸Harvard Medical School, Boston, MA, ⁹Department of Medicine, Brigham and Women's Hospital, Boston, MA, ¹⁰Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹¹Innlandet Hospital Trust, Brumunddal, Norway
Background/Purpose: Inflammatory rheumatic diseases (IRDs) are associated with accelerated atherosclerosis, which progression is related to inflammation (1). One of the first stages in atherogenesis is…
Abstract Number: 1738 • 2016 ACR/ARHP Annual Meeting
Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison
Peter Nash¹, Iain B McInnes², Philip J Mease³, Ernest H. Choy^4,5, Howard Thom⁶, Chrysostomos Kalyvas⁷, Kunal Gandhi⁸, Shephard Mpofu⁹ and Steffen Jugl⁹, ¹Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, ⁶University of Bristol, Bristol, United Kingdom, ⁷MAPI Group, Houten, Netherlands, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and adalimumab (ADA) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. A head-to-head…
Abstract Number: 1680 • 2016 ACR/ARHP Annual Meeting
Apremilast Monotherapy As the First Systemic Treatment in DMARD-Naive Patients with Active Psoriatic Arthritis: 3-Year Treatment Results
Alvin F. Wells¹, Christopher J. Edwards^2,3, Alan J. Kivitz⁴, Paul Bird⁵, Dianne Nguyen⁶, Kamal Shah⁶, Lichen Teng⁶ and Jacob A Aelion⁷, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University of Southampton, Southampton, United Kingdom, ³University Hospital Southampton, Southampton, United Kingdom, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Combined Rheumatology Practice, Kogarah, Australia, ⁶Celgene Corporation, Summit, NJ, ⁷West Tennessee Research Institute, Jackson, TN
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes joint inflammation and other manifestations of psoriatic arthritis…
Abstract Number: 1740 • 2016 ACR/ARHP Annual Meeting
Long-Term Improvements in Physical Function of DMARD-Naive and DMARD/Biologic-Experienced Psoriatic Arthritis Patients Treated with Apremilast: Data from a Large Database of 4 Phase III Clinical Trials
Philip J Mease¹, Alvin F Wells², Jürgen Wollenhaupt³, Stephen Hall⁴, Filip van Den Bosch⁵, Eric Lespessailles⁶, Melissa McIlraith⁷, Dianne Nguyen⁷, Lichen Teng⁷ and Christopher J Edwards⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Rheumatology & Immunotherapy Center, Franklin, WI, ³Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵UZ Gent, Gent, Belgium, ⁶University of Orléans, Orléans, France, ⁷Celgene Corporation, Summit, NJ, ⁸University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: Improving and preserving patient (pt) physical function is an important goal in managing psoriatic arthritis (PsA). Apremilast (APR) has been shown to improve signs…
Abstract Number: 1683 • 2016 ACR/ARHP Annual Meeting
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Renganayaki Pandurengan², Christopher T. Ritchlin⁴, Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Although spinal involvement has been well studied in ankylosing spondylitis,1 very few studies in psoriatic arthritis (PsA) have characterized patients with axial involvement. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].